Table 1 Baseline demographic and clinical characteristics of 17 patients
| Â | Â | Â | Â | Â | Thyroid autoantibody | At baseline | During sunitinib-Tx | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient | Gender/age (year) | Pre-Tx with IFN/duration (months) | Total cycle of sunitinib | Best response by sunitinib | Thyroglobilin antibody (IU ml–1) | TPO antibody (IU ml–1) | Thyroid volume (ml) | TSH (mIu l–1) | Status | Thyroid volume (ml) | TSH (mIu l–1) | Status |
 1 | F/44 | No | 9 | PR | <0.15 | <0.15 | 18.5 | 5.06 | Hypo | 8 | 33.15 | Hypoa |
 2 | F/62 | No | 6 | PR | <0.15 | <0.15 | 8.3 | 1.6 | Eu | 2.4 | 117.53 | Hypoa |
 3 | M/65 | No | 23 | CR | — | — | 17.3 |  | Unknown | 1.1 | 137.13 | Hypoa |
 4 | M/64 | No | 11 | SD | — | — | 10.6 | 9.43 | Hypo | 0.4 | 230.89 | Hypoa |
 5 | M/69 | Yes/6 | 10 | PR | <0.15 | <0.15 | 7.8 | 3.62 | Eu | 1.2 | 27.23 | Hypo |
 6 | F/56 | Yes/3 | 20 | PR | — | — | 11.6 | 1.86 | Eu | 1.7 | 42.53 | Hypo |
 7 | F/59 | No | 18 | PR | — | — | 18.2 | 10.14 | Hypo | 6.6 | 19.8 | Hypo |
 8 | F/66 | No | 16 | PR |  |  | 14.3 | 0.61 | Eu | 6.8 | 4.69 | Hypo |
 9 | M/52 | Yes/6 | 6 | PR | — | — | 21 | 1.29 | Eu | 22 | 3.06 | Eu |
10 | F/23 | No | 2 | PD | <0.15 | <0.15 | 8.8 | 8.65 | Hypo | 7.9 | 12.72 | Hypo |
11 | M/65 | Yes/24 | 3 | PR | <0.12 | <0.05 | 13.6 | 1.66 | Eu | 13 | 3.71 | Eu |
12 | M/55 | Yes/3 | 2 | PD | — | — | 11.4 | 0.84 | Eu | 9.5 | 3.91 | Eu |
13 | M/64 | No | 2 | PD | — | — | 12 | 1.07 | Eu | 10 | 3.93 | Eu |
14 | M/78 | Yes/6 | 2 | SD | — | — | 20.2 | 2.24 | Eu | 19.2 | 2.3 | Eu |
15 | F/59 | Yes/6 | 1 | PD | <0.12 | <0.05 | 5.8 | 1.49 | Eu | 2.8 | 3.14 | Eu |
16 | M/76 | Yes/20 | 4 | SD | — | — | 15.6 | 0.65 | Eu | 14 | 3.51 | Eu |
17 | M/45 | Yes/2 | 1 | PD | — | — | 18.9 | 1.57 | Eu | 20.9 | 1.73 | Eu |
